Lupin’s Mandideep Unit II receives EIR from USFDA

Company shows commitment towards enhancing compliance and quality standards

Lupin pacts with Foncoo Pharmaceuticals China. photo youtube

Pharma major Lupin has recently announced the receipt of the Establishment Inspection Report (EIR) after closure of the USFDA inspection of its Mandideep Unit II facility, classifying the inspection as Voluntary Action Indicated. The inspection at the facility was carried out by the USFDA between 26 November 2018 and 4 December 2018.

Commenting on the receipt of the EIR, Nilesh Gupta, managing director, Lupin said, “We are pleased to have received the EIR for our Mandideep Unit II facility, our important cardiovascular API manufacturing facility. We remain committed to enhancing compliance and quality standards across all our manufacturing sites.”


Please enter your comment!
Please enter your name here